Planet Labs PBC (PL)

Planet Labs PBC is trading in a significant downtrend but has bounced sharply. The stock rose 14.50% in the last session on volume 35.2% above its average, and it is up 10.88% over one week. It still sits well below both its 50-day simple moving average of $15.81 and its 200-day simple moving average of $26.30, and it is 72.24% below its 52-week high of $51.76. The rebound is therefore a move inside a long decline, not yet a change of trend.

The stock rose 14.50% in the latest session, on volume 35.2% above its average. Over the past year it is up 12.18%, so the longer-term picture is mixed rather than uniformly weak. The price is 9% of the way up its 52-week range, close to the bottom. A move of this size on heavy volume shows that buyers are willing to step in, but one session does not establish a new trend.

The trend reading is strongly negative: the price is below its 50-day and 200-day moving averages ($15.81 and $26.30), and the 50-day SMA is 39.89% below the 200-day SMA, a configuration that typically reflects a long period of selling. The 14-day RSI is 49.8, in the neutral zone, and the MACD line is negative. Momentum has therefore stopped falling sharply, but it has not turned up convincingly.

The September 3, 2026 report showed EPS of $0.02 against an estimate of -$0.02, a beat of 200.00%. Yet the stock fell 1.25% in the first session after that report. Over the last six reports, four beat estimates, and in each of those four cases the share price was lower in the first session. Reported earnings over the last twelve months are -$1.10 per share, so the P/E is not meaningful. Revenue grew 58.10% in the latest quarter year on year, well ahead of the sector median of 11.7%, but the operating margin of -12.00% shows the business has not yet turned that growth into profit.

At a price-to-sales ratio of 13.82, the stock trades 245.5% above the sector median of 4.0. Return on equity is -71.97%, against a sector median of 17.8%, and the debt-to-equity ratio is 0.88. The company pays no dividend. Investors are paying a premium for growth, and the premium depends on losses narrowing.

The base case is that the stock keeps trading inside a wide range while it tries to reclaim its moving averages. For the trend to turn, the price needs to close above the 50-day SMA at $15.81 and then build on it, something the 200-day SMA at $26.30 has not allowed since the stock fell below it. Analysts are more constructive than the price: the median 12-month target is $28.00, and the range runs from $17.00 to $50.00. Those targets are the analysts' figures, not CleaRank's, and they assume revenue growth continues; analysts expect revenue to grow 42.2% this fiscal year. The case weakens if the stock loses the 20-day EMA at $13.92 and then the 52-week low of $10.52, or if the next quarterly report misses estimates after a string of beats. Losses are still large, with a net profit margin of -95.13%, so margin progress is the key test. Given a beta of 2.27 and a typical daily move of 5.64%, sharp swings in either direction should be expected.

Support sits first at the 20-day EMA of $13.92, which the price is currently holding just above. Below that, the 52-week low of $10.52 is the major floor; a break there would mark a new low for the past year. Resistance starts at the 50-day SMA of $15.81, the level a continued rebound would meet first. The 200-day SMA of $26.30 is the next ceiling and the level that separates a repair of the trend from a short-term bounce. The 52-week high of $51.76 is the distant ceiling, far above the current price.